Your browser doesn't support javascript.
loading
Dynamics of circulating vascular endothelial growth factor-A predict benefit from antiangiogenic cediranib in metastatic or recurrent cervical cancer patients.
Zhou, Cong; Taylor, Sarah; Tugwood, Jonathan; Simpson, Kathryn; Jayson, Gordon C; Symonds, Paul; Paul, James; Davidson, Susan; Carty, Karen; McCartney, Elaine; Rai, Debbie; Dive, Caroline; West, Catharine.
Afiliación
  • Zhou C; Division of Cancer Sciences, University of Manchester, Manchester Academic Health Science Centre, Manchester, UK.
  • Taylor S; Clinical & Experimental Pharmacology Group, Cancer Research UK Manchester Institute and Manchester Centre for Cancer Biomarker Sciences, University of Manchester, UK.
  • Tugwood J; Clinical & Experimental Pharmacology Group, Cancer Research UK Manchester Institute and Manchester Centre for Cancer Biomarker Sciences, University of Manchester, UK.
  • Simpson K; Clinical & Experimental Pharmacology Group, Cancer Research UK Manchester Institute and Manchester Centre for Cancer Biomarker Sciences, University of Manchester, UK.
  • Jayson GC; Clinical & Experimental Pharmacology Group, Cancer Research UK Manchester Institute and Manchester Centre for Cancer Biomarker Sciences, University of Manchester, UK.
  • Symonds P; Division of Cancer Sciences, University of Manchester, Christie Hospital NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK.
  • Paul J; Department of Cancer Studies, University of Leicester, Leicester, UK.
  • Davidson S; Cancer Research UK Clinical Trials Unit, Institute of Cancer Sciences, University of Glasgow, Glasgow, UK.
  • Carty K; Christie Hospital NHS Trust, Manchester, UK.
  • McCartney E; Cancer Research UK Clinical Trials Unit, Institute of Cancer Sciences, University of Glasgow, Glasgow, UK.
  • Rai D; Cancer Research UK Clinical Trials Unit, Institute of Cancer Sciences, University of Glasgow, Glasgow, UK.
  • Dive C; Cancer Research UK Clinical Trials Unit, Institute of Cancer Sciences, University of Glasgow, Glasgow, UK.
  • West C; Clinical & Experimental Pharmacology Group, Cancer Research UK Manchester Institute and Manchester Centre for Cancer Biomarker Sciences, University of Manchester, UK.
Br J Clin Pharmacol ; 85(8): 1781-1789, 2019 08.
Article en En | MEDLINE | ID: mdl-30980733
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Contexto en salud: 6_ODS3_enfermedades_notrasmisibles Problema de salud: 6_cervical_cancer Asunto principal: Quinazolinas / Protocolos de Quimioterapia Combinada Antineoplásica / Biomarcadores de Tumor / Neoplasias del Cuello Uterino / Factor A de Crecimiento Endotelial Vascular / Recurrencia Local de Neoplasia Tipo de estudio: Clinical_trials / Prognostic_studies / Risk_factors_studies Límite: Adult / Aged / Female / Humans / Middle aged Idioma: En Revista: Br J Clin Pharmacol Año: 2019 Tipo del documento: Article País de afiliación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Contexto en salud: 6_ODS3_enfermedades_notrasmisibles Problema de salud: 6_cervical_cancer Asunto principal: Quinazolinas / Protocolos de Quimioterapia Combinada Antineoplásica / Biomarcadores de Tumor / Neoplasias del Cuello Uterino / Factor A de Crecimiento Endotelial Vascular / Recurrencia Local de Neoplasia Tipo de estudio: Clinical_trials / Prognostic_studies / Risk_factors_studies Límite: Adult / Aged / Female / Humans / Middle aged Idioma: En Revista: Br J Clin Pharmacol Año: 2019 Tipo del documento: Article País de afiliación: Reino Unido